FDA approves new combination treatment for acute myeloid leukemia

On April 28, the U.S. Food and Drug Administration (FDA) approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have the genetic mutation FLT3, in combination with chemotherapy. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here